[1]王 颖,马思蕊,何 旭△.替米沙坦联合培哚普利治疗心力衰竭疗效及对患者左心室射血分数的影响[J].陕西医学杂志,2019,(8):1066-1069.
　WANG Ying,MA Sirui,HE Xu..Efficacy of telmisartan combined with perindopril in the treatment of heart failure and its  effect on left ventricular ejection fraction in patients[J].,2019,(8):1066-1069.
点击复制

替米沙坦联合培哚普利治疗心力衰竭疗效及对患者左心室射血分数的影响
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
期数:
2019年8期
页码:
1066-1069
栏目:
药物与临床
出版日期:
2019-08-05

文章信息/Info

Title:
Efficacy of telmisartan combined with perindopril in the treatment of heart failure and its  effect on left ventricular ejection fraction in patients
文章编号:
DOI:10.3969/j.issn.1000-7377.2019.08.030
作者:
王 颖1; 马思蕊1; 何 旭2△
1.西安市第四医院重症监护室（西安710004）;2.陕西省榆林市第二医院心血管内科（榆林 719000）
Author(s):
WANG Ying;  MA Sirui;  HE Xu.
Department of Intensive Care Unit, Xi’an No.4 Hospital（Xi’an 710004）
关键词:
心力衰竭; 治疗; 替米沙坦; 培哚普利; 心功能; 安全性
Keywords:
Key words Heart failure;  Therapy;  Telmisartan;  Perindopril; Cardiac function;  Security
分类号:
R541.6
文献标志码:
A
摘要:
摘 要 目的：探讨心力衰竭患者应用替米沙坦联合培哚普利治疗的疗效，分析其对患者心功能的影响。方法：选取90例心力衰竭患者作为研究对象，按数字随机表分为对照组45例和观察组45例。对照组单独采用替米沙坦治疗，观察组采用替米沙坦联合培哚普利治疗，比较两组临床治疗总有效率、心功能指标\[（左心室射血分数（LVEF）、心输出量（CO）、心肌耗氧量\]、生存质量（SF-36）评分、日常生活能力（Barthel）指数和不良反应发生率。结果：对照组临床治疗总有效率为82.22%（37/45）；观察组临床治疗总有效率为95.56%（43/45），观察组高于对照组，差异有统计学意义（P＜0.05）。治疗前，对照组和观察组LVEF，CO，心肌耗氧量比较，差异无统计学意义（P＞0.05）；治疗前后LVEF，CO，心肌耗氧量比较，治疗后均优于治疗前，差异有统计学意义（P＜0.05）；治疗3月后，观察组LVEF和CO均高于对照组，心肌耗氧量低于对照组，差异有统计学意义（P＜0.05）。在SF-36评分和Barthel指数方面，治疗前对照组和观察组差异无统计学意义（P＞0.05）；治疗后均高于治疗前，且观察组高于对照组，差异有统计学意义（P＜0.05）。对照组不良反应率为11.10%（5/45），观察组不良反应率为8.88%（4/45），两组比较差异无统计学意义（P＞0.05）。结论：替米沙坦联合培哚普利应用于心力衰竭的治疗中效果明显，可改善患者的心功能，提高患者的生活质量，安全性较高。
Abstract:
Abstract Objective: To analyze the effect of telmisartan combined with perindopril on cardiac function in patients with heart failure, so as to provide more reliable theoretical reference for clinical treatment and improve the level of diagnosis and treatment of heart failure. Methods: 90 cases of heart failure patients admitted to the department of cardiovascular medicine were selected as the research objects, and were randomly divided into 45 cases in the control group and 45 cases in the observation group according to the numerical table. The control group was treated with telmisartan alone, while the observation group was treated with telmisartan combined with perindopril. The total effective rate, cardiac function index (LVEF, CO, myocardial oxygen consumption), quality of life (SF-36) score, Barthel index and incidence of adverse reactions were compared between the two groups. Results: The total effective rate in the control group was 82.22% (37/45). The total effective rate of clinical treatment in the observation group was 95.56% (43/45), which was higher in the observation group than the control group, and the difference was statistically significant (P＜0.05). Before treatment, LVEF, CO and myocardial oxygen consumption of the control group and the observation group were compared, and the difference was not statistically significant (P>0.05). LVEF, CO and myocardial oxygen consumption before and after treatment were better than before treatment, and the difference was statistically significant (P＜0.05). After 3 months of treatment, both LVEF and CO in the observation group were higher than those in the control group, and the myocardial oxygen consumption was lower than that in the control group, with statistically significant difference (P＜0.05). In terms of sf-36 score and Barthel index, there was no significant difference between the control group and the observation group before treatment (P>0.05). The difference was statistically significant (P＜0.05). The adverse reaction rate of the control group was 11.10% (5/45), and that of the observation group was 8.88% (4/45), with no statistically significant 〖LM〗difference between the two groups (P>0.05).Conclusion: Telmisartan combined with perindopril in the treatment of heart failure is effective, can improve the patient's heart function, improve the patient's quality of life, high safety, worthy of promotion and application.

参考文献/References:

[1] 王俊锋.他汀类药物在慢性心力衰竭治疗中的临床效果评价[J]. 临床医学研究与实践, 2016, 1(14):48-48.
[2] Matsumoto Y, Mori Y, Kageyama S, et al. Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodial-ysis patients[J]. Journal of the American College of Cardiology, 2014, 63 (6):528-536．
[3] 魏淑岩,王德良,王新华.芪苈强心胶囊联合西药治疗不同中医证型慢性心力衰竭疗效观察[J].陕西中医,2017,38(1):18-19.
[4] 中华医学会心血管病学分会. 中国心力衰竭诊断和治疗指南2014[J]. 中华心血管病杂志, 2014, 42(2):3-10.
[5] Tegn N, Abdelnoor M, Aaberge L, et al. Invasive versus conservative strategy in patients aged 80 years or older with non-ST-elevation myocardial infarction or unstable angina pectoris (After Eighty study): an open-label randomised controlled trial [J]. Lancet, 2016, 387(10023):1057-1065.
[6] 魏 钢,杨晓飞.生脉散合丹参饮联合西药治疗慢性心力衰竭疗效研究[J].陕西中医,2018,39(12)：1702-1704,1708.
[7] Fu R,Xiang J,Bao H,et al. Association between process indicators and in-hospital mortality among patients with chronic heart failure in China[J]. Eur J Public Health,2015,25(3):373-8.
[8] Ewen S,Bohm M. Too much is too much: evidence against dual RAAS inhibition in hypertensives with heart failure symptoms[J]. Eur Heart J,2015,36(15):899-901.
[9] 朱玉江, 邢晓龙, 王西辉.托拉塞米联合培哚普利治疗心力衰竭的临床研究[J].现代药物与临床,2017, 32(9):1631-1634.
[10] 王贵鹏, 吕忠英, 向 阳. 环磷腺苷葡胺联合培哚普利在慢性心力衰竭中的应用研究[J].现代生物医学进展, 2017, 17(19):3707-3710.

相似文献/References:

[1]周岩芬,张敏,周万保,等.NT-proBNP、肥胖及心力衰竭风险之间的相关性研究[J].陕西医学杂志,2016,(09):1163.
[2]张敏,张科林.托拉塞米联合多巴胺对老年顽固性心衰疗效及脑钠肽的影响[J].陕西医学杂志,2016,(09):1226.
[3]熊三军,马江伟,乔增勇.重组人脑利钠肽治疗心力衰竭临床效果及对患者尿量、心功能、炎症指标的影响[J].陕西医学杂志,2019,(1):99.
[4]徐 博,苏军涛,钟 烨,等.外源性Apelin13对重症急性胰腺炎大鼠治疗作用及其机制研究*[J].陕西医学杂志,2019,(2):148.
　XU Bo,SU Juntao,ZHONG Ye,et al.Effect and mechanism of exogenous apelin13 on severe acute pancreatitis in rats[J].,2019,(8):148.
[5]陈保春,刘利峰.铥激光与等离子电切术治疗膀胱癌疗效对比研究*[J].陕西医学杂志,2019,(2):159.
　CHEN Baochun,LIU Lifeng..Comparative study of thulium laser and plasma electroresection in resection of bladder tumor[J].,2019,(8):159.
[6]张玉亮,朱 宏,戴洪山△.B超引导经皮经肝胆囊穿刺引流术在胆源性胰腺炎治疗中的临床意义[J].陕西医学杂志,2019,(2):166.
　ZHANG Yuliang,ZHU Hong,DAI Hongshan..Clinical significance of Bmode ultrasound guided percutaneous transhepatic  gallbladder puncture and drainage in the treatment of biliary pancreatitis[J].,2019,(8):166.
[7]徐建庆,买赛虎△,杨喜佳,等.腹腔镜手术治疗复杂性胆囊炎临床疗效研究[J].陕西医学杂志,2019,(2):176.
　XU Jianqing,MAI Saihu,YANG Xijia,et al.Analysis of curative effect in laparoscopic surgery for complicated cholecystitis[J].,2019,(8):176.
[8]刘 侃,杨栓元,刘旭晨,等.PPH术治疗III、IV度痔中长期疗效研究[J].陕西医学杂志,2019,(2):183.
　LIU Kan,YANG Shuanyuan,LIU Xucheng,et al.Curative effect of PPH for III and IV hemorrhoids[J].,2019,(8):183.
[9]石 丹,张会久,周达岸.闭合复位经皮空心螺钉内固定与切开复位内固定治疗踝关节骨折疗效对比研究[J].陕西医学杂志,2019,(2):186.
　SHI Dan,ZHANG Huijiu,ZHOU Daan..Comparison of closed reduction, percutaneous cannulated screw fixation and open reduction  and internal fixation for ankle fractures[J].,2019,(8):186.
[10]肖东波.不保留小关节植骨床PLIF术治疗老年脊柱退行性疾病价值研究*[J].陕西医学杂志,2019,(2):189.
　XIAO Dongbo..The value of nonreserving small arthroplasty bone PLIF for senile spinal degenerative diseases[J].,2019,(8):189.

更新日期/Last Update: 2019-08-13